Illumina Launches BioInsight Platform with DRAGEN v4.6 for Unified Genomic Analysis

Illumina Introduces Unified Genomics Software Platform

Illumina, Inc. debuted the BioInsight Platform on Wednesday, marking a significant shift in how researchers analyze genomic and multiomic data1

1

2

2

. The unified genomics software platform consolidates Illumina's analysis applications, AI innovations, and curated data resources into a single sign-on environment, eliminating the need for researchers to assemble and manage separate informatics tools as their research questions evolve. The company created its BioInsight business unit one year ago specifically to address the gap between generating large-scale genomic datasets and converting them into actionable biological insights.

DRAGEN v4.6 Expands Deployment Flexibility

The BioInsight Platform includes DRAGEN v4.6, the latest version of Illumina's award-winning secondary analysis software2

2

. The new DRAGEN software mode allows organizations to run the analysis tool across supported cloud and standard CPU environments, significantly expanding deployment options beyond previous versions. This update delivers consistent analysis across supported compute environments, giving organizations more flexibility to run DRAGEN in the environment that best fits their operational needs while maintaining confidence in their results. The expanded deployment capabilities matter because they allow research institutions to optimize their computational infrastructure costs while maintaining analytical consistency.

AI Innovations Drive Rare Disease Research Forward

The BioInsight Platform provides researchers access to Illumina's portfolio of genomic AI innovations, including the newly announced SpliceAI2 model specifically designed for rare disease research2

2

. The BioInsight AI Lab, the research arm of BioInsight, applies multiomic data and AI for variant effect prediction, variant effect prioritization, and biological foundation model training. These purpose-built AI models help researchers identify, prioritize, and interpret biologically relevant signals across increasingly complex datasets, enabling deeper exploration of disease biology and genetic variation. The platform's AI capabilities represent a fundamental shift from traditional genomic analysis tools, as they can process and contextualize information at scales previously unmanageable for human researchers.

Global Parkinson's Genetics Program Leverages New Capabilities

Researchers are already deploying DRAGEN software mode to support large-scale genomic discovery efforts. The Global Parkinson's Genetics Program, a resource program of Aligning Science Across Parkinson's in partnership with The Michael J. Fox Foundation for Parkinson's Research, is using DRAGEN software mode to support approximately 170 active research projects investigating the genetic basis of Parkinson's disease1

1

2

2

. Faster processing and the ability to run analyses efficiently and consistently on a public cloud environment is helping GP2 accelerate and share their large genomic cohort studies, demonstrating real-world impact on critical disease research.

Curated Datasets Span Multiple Research Domains

The BioInsight Platform features expertly curated datasets for research spanning oncology, rare disease, population health research, and multiomics1

1

2

2

. BioInsight Data converts public and proprietary datasets into a harmonized, annotated, and reusable scientific catalog, alongside AI models designed specifically for genomics and multiomics applications. These continuously updated datasets enable researchers to contextualize findings across studies, generate new hypotheses, and accelerate biological discovery. The platform brings together Illumina's growing portfolio of informatics applications, including DRAGEN, Emedgene, Connected Multiomics, BioInsight Platform Core, BaseSpace, and BioInsight Data.

Usage-Based Credits Model Replaces Traditional Subscriptions

The BioInsight Platform operates on a usage-based credits model, replacing traditional annual subscriptions1

1

2

2

. This pricing structure lets researchers adopt the capabilities most relevant to their work while maintaining flexibility to evaluate new technologies as scientific needs evolve. "BioInsight was built on an incredible history of data, software, and AI innovation that Illumina has delivered in the industry for more than a decade," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina1

1

. Illumina will present the platform at the American Society for Human Genetics annual meeting next week in Montreal, and the company offers a free trial of the platform for researchers1

1

. The BioInsight business also includes programs such as the Billion Cell Atlas, which connects proprietary data with leading biopharma partners to help advance the next generation of drug discovery and development2

2

.